A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer

Background: Erlotinib is highly active in EGFR mutant NSCLC, but may benefit some with wild-type tumors. We examined pre-operative erlotinib in early stage NSCLC to assess response and correlation with potential biomarkers. Results: Twenty-five patients were enrolled; 22 received erlotinib treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Sacher, Adrian G., Le, Lisa W., Lara-Guerra, Humberto, Waddell, Thomas K., Sakashita, Shingo, Chen, Zhuo, Kim, Lucia, Zhang, Tong, Kamel-Reid, Suzanne, Salvarrey, Alexandra, Darling, Gail, Yasufuku, Kazuhiro, Keshavjee, Shaf, de Perrot, Marc, Shepherd, Frances A., Liu, Geoffrey, Tsao, Ming Sound, Leighl, Natasha B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041932/
https://www.ncbi.nlm.nih.gov/pubmed/27028852
http://dx.doi.org/10.18632/oncotarget.8350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041932/
https://www.ncbi.nlm.nih.gov/pubmed/27028852
http://dx.doi.org/10.18632/oncotarget.8350

Ejemplares similares